Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × bemarituzumab × Genitourinary × Clear all

Status

No longer available 1

Sponsor Class

Study Type

Interventional 2 Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

gallium 68 PSMA-11 4 Magnetic Resonance Spectroscopy 4 carbon-11 acetate 2 Axitinib 2 Abiraterone Acetate 2 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2 zenocutuzumab 1 ulixertinib 1 tempol 1 tazemetostat 1 talazoparib 1 radium Ra 223 dichloride 1 pegilodecakin 1 omburtamab I-131 1 niraparib 1 motexafin gadolinium 1 enfortumab vedotin 1 dodecyl maltoside 1 bicalutamide 1 bemarituzumab 1 balstilimab 1 atezolizumab 1 apalutamide 1 TEMPOL-H 1 Suspensions 1 Standard of Care 1 Sodium Acetate 1 Proton Pump Inhibitors 1 Prednisone 1 Prednisolone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03801278 2021-12-13

FPA144

Five Prime Therapeutics, Inc.

No longer available

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡